VIRO-25 trial to assess efficacy & safety of olvimulogene nanivacirepvec (Olvi-Vec) & platinum-doublet + physician's choice of immune checkpoint ...
REDWOOD CITY, CA, USA I3, 2024 I Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced encouraging ...
OSLO, Norway I3, 2024 I Calluna Pharma AS (Calluna), a clinical stage biotechnology company pioneering first-in-class antibodies to treat ...
Schrödinger will also present preclinical data from its PRMT5-MTA program during a poster session on October 25. Schrödinger scientists have identified a novel series of selective, potent PRMT5-MTA ...
BASEL, Switzerland I October 23, 2024 I AMYRA Biotech AG (“AMYRA”), a company developing novel, oral digestive enzyme therapeutics for gastrointestinal ...
NEW YORK, NY, USA I October 22, 2024 I SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company and leader in infectious diseases, today announced that it entered into ...
AACHEN, Germany I October 22, 2024 I Today, Grünenthal announced that the first participants have been enrolled in a first-in-human Phase I clinical trial for ...
ROCKVILLE, MD & DEERFIELD, IL, USA I2, 2024 I MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, ...
PRINCETON, NJ, USA & TOKYO, Japan I2, 2024 I Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical, Co. Ltd.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback